Chronological improvement of survival in patients with advanced gastric cancer over 15 years.
Ther Adv Med Oncol
; 16: 17588359241229428, 2024.
Article
in En
| MEDLINE
| ID: mdl-38344409
ABSTRACT
Background:
Recent trials have reported a median overall survival (OS) of 11-17 months in patients with advanced gastric cancer (AGC). However, it is unclear how recently approved drugs contribute to patient prognosis.Objectives:
We aimed to evaluate the characteristics and survival in patients with AGC over the past 15 years.Design:
Retrospective study.Methods:
We evaluated data of 1355 patients with AGC who received first-line chemotherapy between January 2005 and March 2019 at a single institution. We compared the characteristics and survival rates across four periods January 2005-December 2007 (period A), January 2008-February 2011 (period B), March 2011-May 2015 (period C), and June 2015-March 2019 (period D). The median follow-up duration was 13.1 months, with 312, 333, 393, and 317 patients in periods A, B, C, and D, respectively.Results:
There were no significant differences in patient characteristics between the four periods, except for the proportion of patients who underwent prior gastrectomy and human epidermal growth factor receptor 2 (HER2) testing. Patients in period D had significantly longer OS than those in period A [median 15.7 versus 12.4 months; adjusted hazard ratio (aHR) 0.79; p = 0.02]. The mean OS in patients with liver metastasis (LM) in period D was remarkably longer than that in patients in period A (median 19.3 versus 12.4 months; aHR 0.61; p < 0.01), while that in patients with peritoneal metastasis showed limited improvement.Conclusion:
Clinical strategy changes, including gastrectomy, HER2 testing, and approval of new drugs, may be associated with improved OS in patients with AGC. In the last 4 years, a remarkable improvement has been observed in patients with LM.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Language:
En
Journal:
Ther Adv Med Oncol
Year:
2024
Document type:
Article
Affiliation country:
Country of publication: